Atika Capital Management LLC Acquires New Position in Abivax SA Sponsored ADR $ABVX

Atika Capital Management LLC acquired a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 69,000 shares of the company’s stock, valued at approximately $5,858,000. Atika Capital Management LLC owned approximately 0.09% of Abivax at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its holdings in Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after buying an additional 1,990 shares in the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of Abivax by 34.3% during the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after acquiring an additional 2,595 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Abivax by 6.0% in the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after acquiring an additional 56,235 shares during the period. Woodline Partners LP grew its holdings in shares of Abivax by 319.5% in the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock worth $1,262,000 after acquiring an additional 153,788 shares during the period. Finally, XTX Topco Ltd purchased a new position in Abivax in the 2nd quarter valued at approximately $139,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Stock Performance

NASDAQ ABVX opened at $112.31 on Thursday. Abivax SA Sponsored ADR has a fifty-two week low of $4.77 and a fifty-two week high of $148.83. The stock has a market cap of $8.88 billion, a price-to-earnings ratio of -26.87 and a beta of 1.00. The business has a fifty day moving average of $119.71 and a 200-day moving average of $108.36. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The company had revenue of ($4.92) million during the quarter. As a group, analysts predict that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on the company. Morgan Stanley boosted their target price on Abivax from $101.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Wedbush assumed coverage on Abivax in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 price target for the company. Citigroup reaffirmed a “market outperform” rating on shares of Abivax in a research note on Thursday, January 8th. Citizens Jmp boosted their price objective on shares of Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a research report on Tuesday, December 16th. Finally, Truist Financial set a $140.00 price objective on shares of Abivax in a research note on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $134.75.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.